| Similar Articles |
|---|
 |
Fast Company
July 1, 2007 |
Going on the Gold Standard What it takes for your company to join the cancer fight.   |
Science News
May 19, 2007 |
Science Safari: Cancer Risk -- Understanding the Puzzle This new Web site from the National Cancer Institute cuts through the hype to help you understand the plain and simple truth about cancer risk. |
Managed Care
March 2007
Martin Sipkoff |
Managing Cancer Treatment Begins Before Diagnosis Health plans are increasingly involved in promoting the lifestyle changes that help their members avoid cancer, and are increasingly involved in clinical trials if prevention fails. |
Chemistry World
September 28, 2012
Andrew Turley |
Regorafenib approved in US US authorities have approved Stivarga (regorafenib) tablets for the treatment of advanced colorectal cancer. |
AskMen.com
September 30, 2000
Joshua Levine |
Male Breast Cancer Breast cancer is traditionally thought of as a female-related problem. Men, however, are as susceptible to the disease as women are. In many ways, the disease appears similarly in both sexes... |
The Motley Fool
June 28, 2007
Brian Orelli |
Onyx's Hard at Work Onyx's future depends on getting Nexevar approved for new indications. The liver cancer expansion is a nice start, and it should bring Onyx into the black. Investors, take note. |
The Motley Fool
June 17, 2010
Luke Timmerman |
Oncothyreon's Cancer Vaccine Back in the Saddle as Merck KGaA Re-Starts Clinical Trials The German-based Merck got clearance from the FDA and local ethics review boards to resume two of three large pivotal trials. |
American Family Physician
October 1, 2000 |
Genetic Testing for Breast Cancer Risk: What Does It Mean to Me? What causes breast cancer?... What genes can cause breast cancer to be inherited?... What clues in my family history might show I've inherited a risk of breast cancer?... Does everyone who has family members with breast cancer have these mutated genes?... What should I do?... |
Pharmaceutical Executive
February 1, 2013
William Looney |
In Cancer, Process Drives Progress Today's most important public health story is the advance in our understanding of the biology of cancer. |
Chemistry World
September 2, 2014
Phillip Broadwith |
Exelexis slashes workforce by 70% The move follows poor results from a clinical trial of its cancer drug Cometriq (cabozantinib) in men with metastatic castration-resistant prostate cancer. |
The Motley Fool
April 28, 2009
Brian Orelli |
Headline? Bad! Unexpected? No! For a company that only has one drug on the market, stopping a failing phase 3 clinical trial that's designed to expand the market of that drug is usually a major blow. But Onyx Pharmaceuticals was able to shrug it off. |
Science News
June 8, 2002
Janet Raloff |
Pudgy? Here's a Small Benefit For those women whose proportions fall outside the fatfree ideal, here's one consolation: Your outsized physique appears to put you at decreased risk of developing ovarian cancer (a somewhat rare cancer). |
The Motley Fool
August 8, 2007
Brian Orelli |
Onyx Is Almost There Onyx Pharmaceutical narrowed losses for the quarter, and things should improve even more in the months to come, even as their bottom line is still being hampered by endless clinical trials. |
The Motley Fool
September 28, 2010
Brian Orelli |
Pfizer's Sutent Fails. Again! No surprise here. |
ifeminists
October 15, 2002
Sacks & Thompson |
When Men's Health Doesn't Count Congress is sending a message to American men: men's health doesn't count. |
Science News
September 27, 2008
Nathan Seppa |
Hyping Health Risks: Environmental Hazards In Daily Life And The Science Of Epidemiology by Geoffrey Kabat Health scares come and go, but they often have a tenuous scientific basis. Kabat, a cancer epidemiologist, systematically rips through cancer alerts that overrode scientific rigor in recent decades. |
American Family Physician
February 15, 2005 |
Health Care After Cancer Treatment An informative patient hand-out on follow-up cancer care. |
The Motley Fool
December 31, 2010
Brian Orelli |
CEL-SCI Investors Cheer a Bit Too Loudly Finally, a phase 3 trial for cancer therapy Multikine. |
American Family Physician
May 1, 2001 |
Nasopharyngeal Cancer What is nasopharyngeal cancer?... Who might get nasopharyngeal cancer?... What causes nasopharyngeal cancer?... What are some signs of nasopharyngeal cancer?... How is nasopharyngeal cancer treated? |
The Motley Fool
June 2, 2009
Brian Orelli |
Pfizer: If You Can't Beat 'Em, Join 'Em Sutent fails. Again. |
BusinessWeek
May 23, 2005
Catherine Arnst |
If It Works for Breast Cancer... Studies are under way to see if promising strategies used against breast cancer can be used to fight other killers, such as lung, colon, and prostate cancer. |
Chemistry World
November 22, 2013
Emily James |
100 million for cancer research centers Cancer Research UK has invested 100 million pounds in 15 innovative research centers, acquiring high level expertise to solve the latest challenges in cancer. |
American Family Physician
March 15, 2004 |
Breast Cancer Risk Related to Type of Hormone Therapy Although several studies have demonstrated an increased risk of breast cancer in postmenopausal women taking oral hormone therapy, the risk related to each of the various forms of therapy is less clear. |
American Family Physician
May 15, 2005 |
Early Prostate Cancer: What You Should Know A patient hand-out on the disease, who is at risk, diagnosis and treatment options. |
The Motley Fool
February 24, 2004
David Nierengarten |
Cell Genesys Boosted Cell Genesys's shares jump a day late and a dollar higher. |
AskMen.com
Jacob Franek |
Prostate Cancer Overview Everything you wanted to know and more about prostate cancer in this three-part prostate cancer guide. |
The Motley Fool
June 29, 2007
Brian Orelli |
The Phase 2 Blues Drug developer Cytokinetics disappoints investors with failed clinical trials. |
AskMen.com
Jacob Franek |
Testicular Cancer Myths While sometimes deciphering the truth is not simple, we dispel five of the most common myths surrounding testicular cancer. |
The Motley Fool
April 3, 2009
Brian Orelli |
Pfizer + Sutent = One Exciting Roller Coaster This time on the down slope, unfortunately. |
BusinessWeek
February 19, 2007
Gene G. Marcial |
Will Healthy Lab Data Revive Ailing Cell Genesys? Cell genesys is in the midst of clinical trials of vaccines for prostate and pancreatic cancer that analysts believe should catch investors' eyes. |
The Motley Fool
November 20, 2007
Brian Orelli |
Explaining Onyx Pharmaceuticals' Sell-Off The FDA approved Nexavar as a treatment for liver cancer, but the good news causes a sell-off of the stock. |
American Family Physician
March 1, 2004 |
What Should I Know About Stomach Cancer? Stomach cancer, which is also called gastric cancer, is the growth of cells that are not normal in the lining and wall of the stomach. |
The Motley Fool
June 15, 2010
Brian Orelli |
Just Enough to Give Investors Hope Hitting a secondary endpoint means all is not lost for Onyx's lung cancer drug. |
The Motley Fool
March 26, 2007
Rich Duprey |
Acquisitions Mark Pharmaceutical Industry Japan's Eisai's newest acquisition continues the trend of pharmaceuticals buying up biotechs. Investors, take note. |
The Motley Fool
May 28, 2009
Brian Orelli |
Make Money, Fight Disease: The ASCO Preview The big cancer meeting is upon us. |
The Motley Fool
January 11, 2005
Charly Travers |
The Future of Cancer Vaccines Biotech companies developing cancer vaccines have been in investors' doghouses for a long time. Can a vaccine help stave off forms of the disease? |
The Motley Fool
February 27, 2004
Alyce Lomax |
Genentech's Hope For the past two days, Genentech has been an example of what many investors hinge their hopes and dollars on. Yesterday's FDA approval of the company's groundbreaking cancer drug, Avastin, was the reason positive sentiment remained infectious today. |
The Motley Fool
September 9, 2011
Frank Vinluan |
GSK Halts Part of Breast Cancer Trial; Drug Can't Top Herceptin GlaxoSmithKline has halted part of a phase 3 breast cancer clinical study after an independent committee concluded that the GSK drug administered alone is unlikely to work better than a rival cancer drug from Roche. |
The Motley Fool
April 17, 2007
Brian Lawler |
ImClone Loses an Indication ImClone's lead drug fails in a clinical trial. Investors, take note. |
BusinessWeek
May 9, 2005
Catherine Arnst |
Genentech's Lessons For Big Pharma The biotech company focuses on science -- not marketing, acquisitions, or patents. |
The Motley Fool
February 13, 2007
Brian Lawler |
Rock-Solid News From Onyx Results show that the drug Nexavar works in another type of cancer. But investors need to consider other issues when taking a closer look at this pharma. |
The Motley Fool
April 27, 2011
Brian Orelli |
Falling Into the Zaltrap Lung cancer out, colon cancer in phase 3 clinical trial for Regeneron Pharmaceuticals' new drug. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
November 11, 2010
Brian Orelli |
ATTRACTing Clinical Trial Failure Let's not make it a habit, Novartis. Novartis is dropping development of lung-cancer treatment ASA404 after a second failed phase 3 trial. |
The Motley Fool
June 12, 2007
Brian Lawler |
ImClone Tries To Improve Erbitux ImClone is running trials to see if the drug can be used in earlier stages of cancer. Investors shouldn't discount the importance of an approved drug's product label. |
BusinessWeek
July 23, 2007
Gene G. Marcial |
At Ziopharm, Arsenic Is Not So Toxic Ziopharm uses arsenic that is organic. It's stock is rated a buy. |
| AskMen.com |
Good Health Care News New advice from the American Cancer Society puts a sharper focus on the risks of prostate cancer screening, emphasizing that annual testing can lead to unnecessary biopsies and treatments that do more harm than good. |
The Motley Fool
April 5, 2007
Brian Lawler |
ImClone Steps to the Front ImClone announces a successful clinical trial for the cancer drug Erbitux. Investors, take note. |
BusinessWeek
August 15, 2005 |
Misonix Zaps Prostate Cancer Misonix, a maker of medical and scientific gear, has investors interested in its new ultrasound device for prostate cancer. Shares have risen from $5.22 on Apr. 18 to $6.50 on Aug. 3. |
Chemistry World
May 4, 2006
Katharine Sanderson |
Cancer Charity Takes on Shelved Drugs Cancer Research UK, and its commercial arm, Cancer Research Technology have launched a clinical development partnership scheme to sweep up drug candidates that pharmaceuticals companies have deprioritized for not showing enough commercial promise. |
